{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:28:17Z","timestamp":1786332497320,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272911"],"award-info":[{"award-number":["82272911"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003398","name":"Shanxi Scholarship Council of China","doi-asserted-by":"publisher","award":["2023-098"],"award-info":[{"award-number":["2023-098"]}],"id":[{"id":"10.13039\/501100003398","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Shanxi Province Higher Education \u201cBillion Project\u201d Science and Technology Guidance","award":["SY-BYSL-2025020"],"award-info":[{"award-number":["SY-BYSL-2025020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer (BC) has a high incidence and mortality rate among women. Doxorubicin (DOX) is one of the standard chemotherapeutic drugs for BC. However, chemoresistance to DOX represents a major therapeutic obstacle, and its underlying mechanisms remain elusive. CircEGFR (hsa_circ_0080222) is significantly upregulated in BC tissues and drives the malignant progression of BC. However, the role of circEGFR in DOX resistance remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MTT and colony formation assays were used to assess cell growth. Quantitative real\u2011time PCR and western blot were performed to examine gene expression at the mRNA and protein levels, respectively. Spheroid formation and ALDH activity assays were employed to evaluate cell stemness. RNA immunoprecipitation was used to explore the interaction between circEGFR and IGF2BP2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CircEGFR expression was significantly upregulated in DOX-resistant MCF-7 (MCF-7\/DOX) cells. CircEGFR overexpression attenuated DOX sensitivity in MCF-7 cells, as evidenced by increased cell viability and enhanced proliferative capacity. Notably, circEGFR also enhanced cancer stem cell (CSC) properties in BC cells. Conversely, circEGFR knockdown reduced chemoresistance and stem-like properties in both MDA-MB-231 and MCF-7\/DOX cells. Mechanistically, circEGFR interacted with IGF2BP2 to enhance the stability of the stem cell marker SOX2 mRNA, resulting in elevated SOX2 expression. Rescue experiments demonstrated that silencing IGF2BP2 or SOX2 abrogated circEGFR-mediated chemoresistance and stemness properties in BC cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study demonstrates for the first time that circEGFR drives DOX chemoresistance and maintains cancer stemness in BC cells via the IGF2BP2\/SOX2 axis. Targeting circEGFR may be considered a promising therapeutic strategy for overcoming chemotherapy resistance in BC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/stmcls\/sxag032","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:46:26Z","timestamp":1778931986000},"source":"Crossref","is-referenced-by-count":0,"title":["Circular RNA circEGFR overexpression attenuates chemosensitivity and enhances cancer stemness via targeting IGF2BP2\/SOX2 in breast cancer cells"],"prefix":"10.1093","volume":"44","author":[{"given":"Xinran","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Shanxi Medical University , Taiyuan, 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Shanxi Medical University , Taiyuan, 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijian","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Shanxi Medical University , Taiyuan, 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Shanxi Medical University , Taiyuan, 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Shanxi Medical University , Taiyuan, 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Shanxi Medical University , Taiyuan, 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Shanxi Medical University , Taiyuan, 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Shanxi Provincial People\u2019s Hospital, Fifth Hospital of Shanxi Medical University , Taiyuan, 030012,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3165-6227","authenticated-orcid":false,"given":"Xiaoxia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Shanxi Medical University , Taiyuan, 030001,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026080922380647500_sxag032-B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026080922380647500_sxag032-B2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s13346-024-01648-0","article-title":"A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer","volume":"15","author":"Bisht","year":"2025","journal-title":"Drug Deliv Transl Res"},{"key":"2026080922380647500_sxag032-B3","doi-asserted-by":"publisher","first-page":"1619597","DOI":"10.3389\/fcell.2025.1619597","article-title":"Cancer stem cells in personalized therapy: mechanisms, microenvironment crosstalk, and therapeutic vulnerabilities","volume":"13","author":"Yin","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"2026080922380647500_sxag032-B4","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","article-title":"Cancer stem cells: landscape, challenges and emerging therapeutic innovations","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026080922380647500_sxag032-B5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","article-title":"Circular RNA: an emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines","volume":"348","author":"Liu","year":"2022","journal-title":"J Control Release"},{"key":"2026080922380647500_sxag032-B6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41418-022-00948-7","article-title":"Specific expression and functions of circular RNAs","volume":"29","author":"Misir","year":"2022","journal-title":"Cell Death Differ"},{"key":"2026080922380647500_sxag032-B7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41568-024-00721-7","article-title":"Circular RNA in cancer","volume":"24","author":"Conn","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"2026080922380647500_sxag032-B8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41420-025-02494-w","article-title":"Exosomal circRNAs: key modulators in breast cancer progression","volume":"11","author":"Liu","year":"2025","journal-title":"Cell Death Discov"},{"key":"2026080922380647500_sxag032-B9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1080\/15476286.2023.2272468","article-title":"Circular RNAs: biology and clinical significance of breast cancer","volume":"20","author":"Wang","year":"2023","journal-title":"RNA Biol"},{"key":"2026080922380647500_sxag032-B10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41388-024-02950-4","article-title":"Novel exosomal circEGFR facilitates triple negative breast cancer autophagy via promoting TFEB nuclear trafficking and modulating miR-224-5p\/ATG13\/ULK1 feedback loop","volume":"43","author":"Song","year":"2024","journal-title":"Oncogene"},{"key":"2026080922380647500_sxag032-B11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13059-020-02018-y","article-title":"Circatlas: an integrated resource of one million highly accurate circular RNAs from 1070 vertebrate transcriptomes","volume":"21","author":"Wu","year":"2020","journal-title":"Genome Biol"},{"key":"2026080922380647500_sxag032-B12","doi-asserted-by":"publisher","first-page":"W361","DOI":"10.1093\/nar\/gku406","article-title":"Rbpmap: a web server for mapping binding sites of RNA-binding proteins","volume":"42","author":"Paz","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2026080922380647500_sxag032-B13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12915-025-02182-2","article-title":"Rbpsuite 2.0: an updated RNA-protein binding site prediction suite with high coverage on species and proteins based on deep learning","volume":"23","author":"Pan","year":"2025","journal-title":"BMC Biol"},{"key":"2026080922380647500_sxag032-B14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s11658-025-00723-9","article-title":"IGF2BP2: an m6A reader that affects cellular function and disease progression","volume":"30","author":"Liu","year":"2025","journal-title":"Cell Mol Biol Lett"},{"key":"2026080922380647500_sxag032-B15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.32604\/or.2022.027547","article-title":"circRNAs in drug resistance of breast cancer","volume":"30","author":"Misir","year":"2023","journal-title":"Oncol Res"},{"key":"2026080922380647500_sxag032-B16","doi-asserted-by":"publisher","first-page":"1563869","DOI":"10.3389\/fphar.2025.1563869","article-title":"CircASH1L inhibits ferroptosis and enhances cisplatin resistance by sponging miR-515-5p to regulate cell cycle-related CDCA7\/RRM2 in ovarian cancer cells","volume":"16","author":"Feng","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026080922380647500_sxag032-B17","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.62347\/PXHT9575","article-title":"Circular RNA hsa_circ_103089 modulates metabolic glycolysis and influences migration, invasion, and cisplatin sensitivity in non-small cell lung cancer cells via the miR-876-5p\/EGFR axis","volume":"15","author":"Zhou","year":"2025","journal-title":"Am J Cancer Res"},{"key":"2026080922380647500_sxag032-B18","doi-asserted-by":"publisher","first-page":"216023","DOI":"10.1016\/j.canlet.2022.216023","article-title":"CircPTK2\/PABPC1\/SETDB1 axis promotes EMT-mediated tumor metastasis and gemcitabine resistance in bladder cancer","volume":"554","author":"Meng","year":"2023","journal-title":"Cancer Lett"},{"key":"2026080922380647500_sxag032-B19","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1186\/s12864-022-08650-1","article-title":"CircVIS: a platform for circRNA visual presentation","volume":"22","author":"Lin","year":"2022","journal-title":"BMC Genomics"},{"key":"2026080922380647500_sxag032-B20","doi-asserted-by":"publisher","first-page":"e2305142","DOI":"10.1002\/advs.202305142","article-title":"IGF2BP2 drives cell cycle progression in triple-negative breast cancer by recruiting EIF4A1 to promote the m6A-modified CDK6 translation initiation process","volume":"11","author":"Xia","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"2026080922380647500_sxag032-B21","doi-asserted-by":"publisher","first-page":"e12949","DOI":"10.1002\/kjm2.12949","article-title":"IGF2BP2-induced circRNF20 facilitates breast cancer cell proliferation via the HuR\/CDCA4 axis","volume":"41","author":"Wu","year":"2025","journal-title":"Kaohsiung J Med Sci"},{"key":"2026080922380647500_sxag032-B22","doi-asserted-by":"publisher","first-page":"2479926","DOI":"10.1080\/15384047.2025.2479926","article-title":"CircATP5C1 promotes triple-negative breast cancer progression by binding IGF2BP2 to modulate CSF-1 secretion","volume":"26","author":"Liu","year":"2025","journal-title":"Cancer Biol Ther"},{"key":"2026080922380647500_sxag032-B23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-021-01444-1","article-title":"CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502-5p\/KRAS and IGF2BP2\/Myc axes","volume":"20","author":"Li","year":"2021","journal-title":"Mol Cancer"},{"key":"2026080922380647500_sxag032-B24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.semcancer.2019.08.007","article-title":"SOX2 in development and cancer biology","volume":"67","author":"Novak","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"2026080922380647500_sxag032-B25","doi-asserted-by":"publisher","first-page":"188692","DOI":"10.1016\/j.bbcan.2022.188692","article-title":"Understanding the function and regulation of Sox2 for its therapeutic potential in breast cancer","volume":"1877","author":"Dey","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026080922380647500_sxag032-B26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.abb.2018.05.018","article-title":"microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2","volume":"651","author":"Zeng","year":"2018","journal-title":"Arch Biochem Biophys"},{"key":"2026080922380647500_sxag032-B27","doi-asserted-by":"publisher","first-page":"9170","DOI":"10.1038\/s41598-017-08971-2","article-title":"Modulation of SOX2 expression delineates an end-point for paclitaxel-effectiveness in breast cancer stem cells","volume":"7","author":"Mukherjee","year":"2017","journal-title":"Sci Rep"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stmcls\/advance-article-pdf\/doi\/10.1093\/stmcls\/sxag032\/68363943\/sxag032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/44\/8\/sxag032\/68363943\/sxag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/44\/8\/sxag032\/68363943\/sxag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T02:38:15Z","timestamp":1786329495000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/doi\/10.1093\/stmcls\/sxag032\/8690198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,22]]}},"URL":"https:\/\/doi.org\/10.1093\/stmcls\/sxag032","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,21]]},"article-number":"sxag032"}}